SG11201900692WA - Donepezil transdermal delivery system - Google Patents

Donepezil transdermal delivery system

Info

Publication number
SG11201900692WA
SG11201900692WA SG11201900692WA SG11201900692WA SG11201900692WA SG 11201900692W A SG11201900692W A SG 11201900692WA SG 11201900692W A SG11201900692W A SG 11201900692WA SG 11201900692W A SG11201900692W A SG 11201900692WA SG 11201900692W A SG11201900692W A SG 11201900692WA
Authority
SG
Singapore
Prior art keywords
international
donepezil
california
transdermal delivery
july
Prior art date
Application number
SG11201900692WA
Inventor
Eun Soo Lee
Amit K Jain
Parminder Singh
Original Assignee
Corium Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corium Int Inc filed Critical Corium Int Inc
Publication of SG11201900692WA publication Critical patent/SG11201900692WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/0016—Plasticisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates

Abstract

transdermal patch (larger) C.) 30 transdermal patch (smaller) E 20 10 3 4 N co O co O C (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 February 2018 (01.02.2018) WIP0 I PCT onion OH oI0III11010111OHHDIDurnoff ow (10) International Publication Number WO 2018/022817 Al (51) International Patent Classification: A61K 31/445 (2006.01) A61P 25/28 (2006.01) A61K 9/70 (2006.01) (21) International Application Number: PCT/US2017/044050 (22) International Filing Date: 26 July 2017 (26.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/367,542 27 July 2016 (27.07.2016) US 62/367,502 27 July 2016 (27.07.2016) US 62/423,133 16 November 2016 (16.11.2016) US 62/444,745 10 January 2017 (10.01.2017) US 62/444,763 10 January 2017 (10.01.2017) US 62/457,794 10 February 2017 (10.02.2017) US 62/504,408 10 May 2017 (10.05.2017) US 62/504,391 10 May 2017 (10.05.2017) US (71) Applicant: CORIUM INTERNATIONAL, INC. [US/US]; 235 Constitution Drive, Menlo Park, California 94025 (US). (72) Inventors: LEE, Eun Soo; 2575 Hampton Avenue, Red- wood City, California 94061 (US). JAIN, Amit K.; 825 Carino Terrace, Milpitas, California 95035 (US). SINGH, Parminder; 5504 Alvelais Drive, Union City, California 94587 (US). (74) Agent: MOHR, Judy M. et al.; 500 North Capitol Street, N.W., Washington, District of Columbia 20001-1531 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (54) Title: DONEPEZIL TRANSDERMAL DELIVERY SYSTEM Days at Steady State (Week 5) FIG. 5A (57) : A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises drug reservoir layer comprised of an acrylate copolymer, glycerine, and donepezil base generated in situ by reaction of donepezil HC1 and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent that is bioequivalent to administration of the therapeutic agent orally. [Continued on next page] WO 2018/022817 Al IMEDIMOMMIDIRE10101011010H1HOIDERVOIMIE SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
SG11201900692WA 2016-07-27 2017-07-26 Donepezil transdermal delivery system SG11201900692WA (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662367502P 2016-07-27 2016-07-27
US201662367542P 2016-07-27 2016-07-27
US201662423133P 2016-11-16 2016-11-16
US201762444745P 2017-01-10 2017-01-10
US201762444763P 2017-01-10 2017-01-10
US201762457794P 2017-02-10 2017-02-10
US201762504408P 2017-05-10 2017-05-10
US201762504391P 2017-05-10 2017-05-10
PCT/US2017/044050 WO2018022817A1 (en) 2016-07-27 2017-07-26 Donepezil transdermal delivery system

Publications (1)

Publication Number Publication Date
SG11201900692WA true SG11201900692WA (en) 2019-02-27

Family

ID=59523314

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900692WA SG11201900692WA (en) 2016-07-27 2017-07-26 Donepezil transdermal delivery system

Country Status (10)

Country Link
US (9) US20180028463A1 (en)
EP (3) EP3490540A1 (en)
JP (6) JP7251033B2 (en)
KR (9) KR102555208B1 (en)
CN (5) CN109789106B (en)
AU (6) AU2017302306A1 (en)
CA (3) CA3032044A1 (en)
MX (2) MX2019001103A (en)
SG (1) SG11201900692WA (en)
WO (3) WO2018022817A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4349414A2 (en) 2014-12-23 2024-04-10 Dyve Biosciences, Inc. Methods and formulations for transdermal administration
KR20180109859A (en) * 2015-11-18 2018-10-08 커먼웰쓰 사이언티픽 앤드 인더스트리얼 리서치 오가니제이션 Rice grains with thickened hulls
WO2017223402A1 (en) 2016-06-23 2017-12-28 Corium International, Inc. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
AU2017302306A1 (en) 2016-07-27 2019-02-14 Corium, LLC. Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs by in situ salt-to-neutral drug conversion of salt drug
KR102508993B1 (en) 2016-07-27 2023-03-10 코리움, 인크. Memantine Transdermal Delivery System
CA3071007A1 (en) * 2017-07-26 2019-01-31 Corium, Inc. Transdermal delivery system with a microporous membrane having solvent-filled pores
US20190083386A1 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Methods and formulations for transdermal administration of buffering agents
US11173132B2 (en) 2017-12-20 2021-11-16 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
KR20200025883A (en) * 2018-08-31 2020-03-10 에스케이케미칼 주식회사 Rivastigmine patch for long-term administration
KR20200025888A (en) * 2018-08-31 2020-03-10 에스케이케미칼 주식회사 Rivastigmine patch for long-term administration
US11101101B2 (en) * 2019-05-15 2021-08-24 Fei Company Laser-based phase plate image contrast manipulation
JP2022554147A (en) * 2019-10-24 2022-12-28 エルテーエス ローマン テラピー－ジステーメ アーゲー Transdermal therapeutic system for transdermal administration of fingolimod
EP4066829A4 (en) * 2019-11-26 2023-12-27 Hisamitsu Pharmaceutical Co., Inc. Method for improving holding power of adhesive agent layer in ropinirole-containing transdermal patch, and ropinirole-containing transdermal patch having improved holding power
US20230357787A1 (en) * 2019-12-18 2023-11-09 Pioneer Hi-Bred International, Inc. Compositions and methods for improving grain yield in plants
AU2021256454A1 (en) * 2020-04-14 2022-09-29 Glanis Pharmaceuticals, Inc. Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine
US20220364106A1 (en) * 2021-05-14 2022-11-17 Board Of Trustees Of Southern Illinois University Compositions and Methods to Increase Oleic Acid Content in Soybeans
AU2022306570A1 (en) * 2021-07-08 2024-01-18 Monsanto Technology Llc Novel insect inhibitory proteins

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
NL134681C (en) 1966-04-26
US3546141A (en) 1966-08-08 1970-12-08 Mc Donnell Douglas Corp Phosphorus-nitrogen polymers and process
NL7305644A (en) 1972-04-20 1973-10-23
DE2856393C2 (en) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Medicines used to treat Parkinson's disease
DE3572485D1 (en) 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
US4880633A (en) 1986-03-12 1989-11-14 Merck & Co., Inc. Transdermal drug delivery system
US4797284A (en) * 1986-03-12 1989-01-10 Merck & Co., Inc. Transdermal drug delivery system
DE3634016A1 (en) 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg AREA-BASED THERAPEUTIC SYSTEM, METHOD FOR THE PRODUCTION THEREOF AND ITS USE
FI95572C (en) * 1987-06-22 1996-02-26 Eisai Co Ltd Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt
US4837027A (en) 1987-11-09 1989-06-06 Alza Corporation Transdermal drug delivery device
US4781924A (en) 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
US4849224A (en) 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
US5026556A (en) 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
DE58905637D1 (en) 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Use of adamantane derivatives for the prevention and treatment of cerebral ischemia.
DE3913734C2 (en) 1989-04-26 1998-08-20 Roehm Gmbh Use of an aqueous skin pressure sensitive adhesive solution for producing an adhesive layer which can be easily washed off with water
MY115126A (en) * 1990-04-27 2003-04-30 Seikisui Chemical Co Ltd Percutaneously absorbable eperisone or tolperisone preparation.
US5252588A (en) * 1990-04-27 1993-10-12 Sekisui Kagaku Kogyo Kabushiki Kaisha Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation
IE62597B1 (en) 1990-07-23 1995-02-08 Alza Corp Oral osmotic device for delivering nicotine
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5123900A (en) * 1991-08-16 1992-06-23 Bertek, Inc. Moisture permeable double disk
JPH06199659A (en) 1992-10-28 1994-07-19 Hisamitsu Pharmaceut Co Inc Apparatus for percutaneous treatment
DE4310012A1 (en) 1993-03-27 1994-09-29 Roehm Gmbh Dermal therapeutic system made of a meltable poly (meth) acrylate mixture
US5424077A (en) 1993-07-13 1995-06-13 Church & Dwight Co., Inc. Co-micronized bicarbonate salt compositions
US5733900A (en) * 1994-04-21 1998-03-31 Hisamitsu Pharmaceutical Co., Inc. Percutaneous administration base composition and percutaneous administration medicinal composition comprising said base composition and medicine
ATE194281T1 (en) 1994-09-14 2000-07-15 Minnesota Mining & Mfg TRANSDERMAL ACTIVE RELEASE MATRIX
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
CA2208132A1 (en) 1994-12-21 1996-06-27 Theratech, Inc. Transdermal delivery system with adhesive overlay and peel seal disc
AU6032696A (en) 1995-06-07 1996-12-30 Cygnus Therapeutic Systems Pressure sensitive acrylate adhesive composition cross-linke d with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group
DE19531342B4 (en) 1995-08-25 2007-11-29 Merz Pharma Gmbh & Co. Kgaa Use of aminoadamantane compounds as immunoregulators
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5958919A (en) 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
EP0934078B1 (en) 1996-10-24 2002-12-18 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
CN1174031A (en) 1997-04-23 1998-02-25 谢先运 Diclofenac sodium skin-penetrating delayed plaster
US5866585A (en) 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US20040018241A1 (en) 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6193993B1 (en) 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
JP4205778B2 (en) * 1998-04-17 2009-01-07 久光製薬株式会社 Patch preparation
DE19820999A1 (en) 1998-05-11 1999-11-18 Lohmann Therapie Syst Lts Layered medicinal adhesive plaster with high holding power and flexibility
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US20020192243A1 (en) * 1999-12-16 2002-12-19 Tsung-Min Hsu Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
JP3962684B2 (en) * 2000-11-06 2007-08-22 サムヤン コーポレイション Transdermal agent having improved water absorption and adhesion
JP4057418B2 (en) * 2000-11-07 2008-03-05 久光製薬株式会社 Transdermal preparation
JP4850346B2 (en) * 2001-03-15 2012-01-11 救急薬品工業株式会社 Mucosal patch
JP4116447B2 (en) 2001-05-01 2008-07-09 エイ．ブイ．トップチーブ インスティテュート オブ ペトロケミカル シンセシス Hydrogel composition
WO2003015713A2 (en) 2001-08-20 2003-02-27 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
EP1423100B1 (en) 2001-09-04 2007-01-24 Trommsdorff GmbH & Co.KG Arzneimittel Plaster comprising sertaconazole for the treatment of dysfunctions and disorders of nails
ITMI20012827A1 (en) 2001-12-28 2003-06-28 Fidia Farmaceutici TRANSDERMAL ADHESIVE FORMULATIONS OF DICLOFENAC SODIUM
US7273619B2 (en) * 2002-01-17 2007-09-25 Samyang Corporation Transdermal composition of an antivomiting agent
CN100339070C (en) 2002-10-24 2007-09-26 莫茨药物股份两合公司 Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
PT1670433E (en) 2003-10-10 2012-02-08 Ferring Bv Transdermal pharmaceutical formulation for minimizing skin residues
CA2542753A1 (en) * 2003-10-14 2005-04-28 Dermatrends, Inc. Enhancing transdermal administration of hydrophilic drugs
EP1682109B1 (en) 2003-10-22 2008-10-15 Merz Pharma GmbH & Co. KGaA The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic as peptides in amyloidopathies
EP1691848B1 (en) 2003-10-23 2012-08-22 TRANS1, Inc. Tools and tool kits for performing minimally invasive procedures on the spine
EP1684806B1 (en) 2003-11-21 2008-06-25 Memory Pharmaceuticals Corporation Compositions comprising l-type calcium channel blockers and cholinesterase inhibitors
US7176185B2 (en) 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
KR20150038745A (en) 2004-02-17 2015-04-08 트랜스셉트 파마슈티칼스, 인코포레이티드 Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US7670838B2 (en) 2004-05-24 2010-03-02 The Board Of Trustees Of The Leland Stanford Junior University Coupling of excitation and neurogenesis in neural stem/progenitor cells
US20080038328A1 (en) 2004-05-28 2008-02-14 Naruhito Higo Pasting Preparation
TW200616608A (en) 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20060078604A1 (en) 2004-10-08 2006-04-13 Noven Pharmaceuticals, Inc. Transdermal drug delivery device including an occlusive backing
EP1661560B1 (en) 2004-11-22 2008-11-05 Hisamitsu Pharmaceutical Co., Inc. Transdermal patch comprising a melting point lowering agent
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
SI1836157T1 (en) 2005-01-11 2009-12-31 Teva Pharm Fine Chemicals Srl Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride
JP5084496B2 (en) * 2005-02-04 2012-11-28 久光製薬株式会社 Transdermal patch
US20060188558A1 (en) * 2005-02-18 2006-08-24 Mylan Technologies, Inc. Transdermal systems having control delivery system
WO2006121560A2 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US7888422B2 (en) 2005-11-09 2011-02-15 Mylan Technologies Inc. Long-wearing removable pressure sensitive adhesive
WO2007110080A2 (en) * 2006-03-28 2007-10-04 Amcor Flexibles Denmark A/S A multilayer film free of halogens which is impermeable to aroma compounds
CN1895242B (en) 2006-04-13 2011-08-31 沈阳药科大学 Diclofenac salt pleximetric paste and its production
IL175338A0 (en) 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
AU2006343077B2 (en) * 2006-05-08 2012-11-08 Teikoku Seiyaku Co., Ltd. Tansdermally absorbable preparation comprising anti-dementia agent
JP5097359B2 (en) 2006-05-09 2012-12-12 久光製薬株式会社 Donepezil transdermal preparation
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
US9248104B2 (en) * 2006-08-17 2016-02-02 Core Tech Solutions, Inc. Transdermal methods and systems for treating Alzheimer's disease
US20080107719A1 (en) 2006-11-08 2008-05-08 Sukhon Likitlersuang Transdermal drug delivery system
KR101408488B1 (en) * 2006-12-01 2014-06-17 닛토덴코 가부시키가이샤 Method for prevention of discoloration with time of donepezil-containing skin adhesive preparation
CN101568340B (en) * 2006-12-01 2011-06-15 日东电工株式会社 Percutaneous absorption preparation
EP2098233A4 (en) 2006-12-01 2012-03-21 Nitto Denko Corp Skin adhesive preparation comprising stabilized donepezil
JP5403948B2 (en) 2007-06-07 2014-01-29 久光製薬株式会社 Memantine-containing transdermal absorption preparation
BRPI0814697B8 (en) 2007-07-10 2021-05-25 Agile Therapeutics Inc drug delivery device
US9017301B2 (en) * 2007-09-04 2015-04-28 Mylan Technologies, Inc. Transdermal drug delivery systems comprising a coated release liner
JP2009203213A (en) * 2008-02-28 2009-09-10 Kosumedei Seiyaku Kk Percutaneous absorption pharmaceutical composition
DE102008013701A1 (en) * 2008-03-11 2009-09-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with stabilized membrane
KR101454362B1 (en) 2008-03-24 2014-10-23 아이큐어 주식회사 Percutaneous absorption preparations for the treatment of dementia containg donepezil as an active ingredient
EP2111857A1 (en) * 2008-04-25 2009-10-28 Acino AG Transdermal therapeutic system for application of fentanyl or an analogue material thereof
US20090291127A1 (en) 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
PE20100371A1 (en) 2008-10-31 2010-06-01 Lexicon Pharmaceuticals Inc S1P RECEPTOR AGONISTS FOR THE TREATMENT OF CEREBRAL MALARIA
US20100178037A1 (en) 2009-01-12 2010-07-15 Te-Wei Chen Display apparatus, video generation apparatus, and method thereof
US8784879B2 (en) 2009-01-14 2014-07-22 Corium International, Inc. Transdermal administration of tamsulosin
JP5758290B2 (en) 2009-05-01 2015-08-05 久光製薬株式会社 Transdermal preparation
KR101325104B1 (en) 2009-09-16 2013-11-07 주식회사 삼양바이오팜 Transdermal delivery system and method for manufacturing the same
JP5913981B2 (en) 2009-10-21 2016-05-11 帝國製薬株式会社 Donepezil-containing transdermal preparation
CN102048678A (en) * 2009-10-30 2011-05-11 北京隆旗生物科技有限公司 Transdermal absorption preparation of oxybutynin as well as preparation method and medication application thereof
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
JP2012236773A (en) * 2009-12-16 2012-12-06 Goto Takeshi Transdermally absorbable preparation of anti-dementia drug
CA2785639A1 (en) 2009-12-30 2011-07-07 Novartis Ag Melt extruded nicotine thin strips
US20100178307A1 (en) 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
JP5615898B2 (en) * 2010-02-24 2014-10-29 久光製薬株式会社 Patch
US20110244023A1 (en) * 2010-03-30 2011-10-06 Phosphagenics Limited Transdermal delivery patch
EP2564848B1 (en) 2010-04-28 2015-09-02 Hisamitsu Pharmaceutical Co., Inc. Transdermally absorbable donepezil-containing preparation
WO2011146583A2 (en) 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
DE102010024105A1 (en) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermal administration of memantine
US20140370076A1 (en) 2010-06-30 2014-12-18 Nal Pharmaceuticals, Ltd. Transdermal drug delivery system containing donepezil
NZ605352A (en) * 2010-06-30 2013-10-25 Nal Pharmaceuticals Ltd Process for producing glycosaminoglycans
US10213431B2 (en) 2010-07-29 2019-02-26 Allergan, Inc. Preservative free brimonidine and timolol solutions
BR112013008985A2 (en) 2010-10-12 2016-07-05 Cerecor Inc antitussive compositions comprising memantine
JP5699554B2 (en) 2010-11-11 2015-04-15 富士通株式会社 Vector processing circuit, instruction issue control method, and processor system
CN103200944B (en) 2010-11-17 2016-05-04 赫克萨尔股份公司 The Transcutaneous Therapeutic System that comprises buprenorphine
WO2012084969A1 (en) 2010-12-22 2012-06-28 Hexal Ag Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition
CN103384533A (en) 2010-12-29 2013-11-06 法玛费尔姆有限责任公司 Medicated patch for improved transdermal permeation of diclofenac diethylammonium
TWI433904B (en) 2011-01-12 2014-04-11 Taiwan Biotech Co Ltd Donepezil transdermal patch
CN102775476B (en) * 2011-05-12 2015-01-07 上海天伟生物制药有限公司 Preparation method of micafungin sodium
US8673338B2 (en) 2011-07-29 2014-03-18 Massachusetts Eye And Ear Infirmary Methods of delivering pharmaceutical agents
JP5808214B2 (en) * 2011-09-30 2015-11-10 株式会社トクヤマ Patch
KR101239150B1 (en) 2012-02-28 2013-03-06 에스케이케미칼주식회사 Donepezil-containing transdermal delivery system and process for preparing the same
US9408802B1 (en) * 2012-03-22 2016-08-09 Prosolus, Inc. Seven day drug in adhesive transdermal delivery
US9145907B2 (en) 2012-08-28 2015-09-29 Hsiutao Liang Pipe connector
US20140256690A1 (en) 2013-03-08 2014-09-11 Agile Therapeutics, Inc. Contraceptive method
WO2014174564A1 (en) 2013-04-22 2014-10-30 祐徳薬品工業株式会社 Adhesive patch drug formulation of transdermal absorption type containing memantine
JP5415645B1 (en) 2013-06-28 2014-02-12 久光製薬株式会社 Manufacturing method of patch, patch and package
WO2015031552A1 (en) * 2013-08-30 2015-03-05 3M Innovative Properties Company Estradiol containing transdermal drug delivery systems and compositions
CA2924231C (en) 2013-10-07 2018-04-03 Teikoku Pharma Usa, Inc. Dexmedetomidine transdermal delivery devices and methods for using the same
EP3054933A4 (en) * 2013-10-11 2017-03-15 Teikoku Pharma USA, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
EP3069712B1 (en) * 2013-11-17 2020-09-23 MEDRx Co., Ltd. Transdermal colloidal solution agent
KR101485822B1 (en) 2014-01-22 2015-01-23 주식회사 대웅제약 Transdermal drug delivery system comprising donepezil or its salt
JP2015151370A (en) 2014-02-14 2015-08-24 日東電工株式会社 patch preparation
WO2015200472A1 (en) 2014-06-24 2015-12-30 KAT Transdermals LLC Transdermal delivery system
CA2955241C (en) * 2014-07-18 2023-03-28 Buzzz Pharmaceuticals Limited Oxymorphone transdermal patch
US10925936B2 (en) 2014-09-03 2021-02-23 Nitto Denko Corporation Vaccine pharmaceutical composition for cell-mediated immunity containing bisphosphonates
WO2016046675A1 (en) 2014-09-28 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of neurological diseases
KR101796771B1 (en) 2014-12-18 2017-11-10 아이큐어 주식회사 Transdermal composition comprising donepezil as an active agent
CA2975312A1 (en) 2015-01-28 2016-08-04 Dnx Biotech, Llc Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life
CN108135860A (en) 2015-06-22 2018-06-08 考里安国际公司 Include the transdermal adhesive composition of slightly solubility therapeutic agent
EP3329914A4 (en) 2015-07-27 2019-04-03 Hisamitsu Pharmaceutical Co., Inc. Method for manufacturing asenapine-containing patch
RU2737464C2 (en) * 2015-12-30 2020-11-30 Кориум Интернэшнл, Инк. Systems and methods for prolonged transdermal introduction
CN105693556A (en) * 2016-03-01 2016-06-22 巴斯特医药科技（常州）有限公司 Transformation method for rivastigmine tartrate and patch prepared from product of rivastigmine tartrate
WO2017223402A1 (en) 2016-06-23 2017-12-28 Corium International, Inc. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
KR102508993B1 (en) 2016-07-27 2023-03-10 코리움, 인크. Memantine Transdermal Delivery System
EP3490559A1 (en) 2016-07-27 2019-06-05 Corium International, Inc. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
AU2017302306A1 (en) 2016-07-27 2019-02-14 Corium, LLC. Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs by in situ salt-to-neutral drug conversion of salt drug
CA3071007A1 (en) 2017-07-26 2019-01-31 Corium, Inc. Transdermal delivery system with a microporous membrane having solvent-filled pores

Also Published As

Publication number Publication date
AU2017301928B2 (en) 2023-04-06
CN109789105B (en) 2022-12-27
KR102545649B1 (en) 2023-06-22
KR102406536B1 (en) 2022-06-08
US20180028462A1 (en) 2018-02-01
MX2022006681A (en) 2022-07-11
KR102545643B1 (en) 2023-06-21
US10300025B2 (en) 2019-05-28
US20210015761A1 (en) 2021-01-21
CA3032148A1 (en) 2018-02-01
CA3031945A1 (en) 2018-02-01
AU2023203616A1 (en) 2023-07-06
US10307379B2 (en) 2019-06-04
KR20190034601A (en) 2019-04-02
RU2019105279A (en) 2020-08-27
US20180028663A1 (en) 2018-02-01
EP3490541A2 (en) 2019-06-05
JP2019525932A (en) 2019-09-12
KR102406482B1 (en) 2022-06-08
JP2019523270A (en) 2019-08-22
JP7071330B2 (en) 2022-05-18
KR20220082098A (en) 2022-06-16
KR20230098349A (en) 2023-07-03
US20190247321A1 (en) 2019-08-15
CN109789105A (en) 2019-05-21
AU2023204240A1 (en) 2023-07-27
AU2017301928A1 (en) 2019-02-14
CA3032044A1 (en) 2018-02-01
KR102555208B1 (en) 2023-07-17
JP7153010B2 (en) 2022-10-13
WO2018022817A1 (en) 2018-02-01
US20220016045A1 (en) 2022-01-20
KR20230097203A (en) 2023-06-30
US9993466B2 (en) 2018-06-12
JP2019523268A (en) 2019-08-22
CN109789106A (en) 2019-05-21
KR20230109782A (en) 2023-07-20
WO2018022815A2 (en) 2018-02-01
AU2023203618A1 (en) 2023-07-06
CN109789133A (en) 2019-05-21
US20180028463A1 (en) 2018-02-01
JP2022140751A (en) 2022-09-27
EP3490558A1 (en) 2019-06-05
JP7251033B2 (en) 2023-04-04
US20190247320A1 (en) 2019-08-15
US20180028512A1 (en) 2018-02-01
WO2018022815A3 (en) 2018-03-08
US20180235901A1 (en) 2018-08-23
JP2022121629A (en) 2022-08-19
KR20190035801A (en) 2019-04-03
CN116270551A (en) 2023-06-23
WO2018022816A1 (en) 2018-02-01
EP3490540A1 (en) 2019-06-05
RU2019105279A3 (en) 2020-12-23
JP2022093707A (en) 2022-06-23
CN109789106B (en) 2023-06-27
KR20220082928A (en) 2022-06-17
MX2019001103A (en) 2019-09-27
KR102406528B1 (en) 2022-06-08
AU2017302307A1 (en) 2019-02-14
CN116966166A (en) 2023-10-31
AU2017302306A1 (en) 2019-02-14
KR20190032512A (en) 2019-03-27
KR20220082929A (en) 2022-06-17
US11103463B2 (en) 2021-08-31

Similar Documents

Publication Publication Date Title
SG11201900692WA (en) Donepezil transdermal delivery system
SG11201900712SA (en) Memantine transdermal delivery systems
SG11201803728YA (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201908740VA (en) Sustained release delivery systems comprising traceless linkers
SG11201901445TA (en) A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201811150WA (en) Ev-mediated delivery of binding protein-small molecule conjugates
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201906883SA (en) Methods for the administration of certain vmat2 inhibitors
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201901873PA (en) Tablet compositions
SG11201906222WA (en) Jak1 selective inhibitors
SG11201811760VA (en) Oral dosage form with drug composition, barrier layer and drug layer
SG11201811559WA (en) Cancer treatment combinations
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201811209QA (en) Oral gastroretentive formulations and uses thereof
SG11201407368VA (en) Drug for preventing and/or treating polycystic kidney disease